JAZZ Jazz Pharmaceuticals plc Insider Trading

Director Bruce C Cozadd sold 6,000 shares of JAZZ at $235.12 under scheduled 10b5-1 plan, retains 372.7K shares.

Bruce C Cozadd, a Director of Jazz Pharmaceuticals, sold 6,000 shares (6.0K shares) for $1,410,720.00 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-26, meaning the sale was scheduled rather than discretionary. His post-transaction holdings of 372.7K shares represent a -1.6% reduction from pre-transaction holdings of 378.7K shares, a modest portfolio adjustment. His prior sales at JAZZ show mixed outcomes: three April 2026 sales each yielded 30-day gains of 5.7%-6.6% followed by 90-day gains of 17.9%-18.9%, while two March 2026 sales had near-flat 30-day performance (0.1%-0.5%) before 90-day gains of 24.6%-25.0%. The current market context shows JAZZ trading at $230.93, down 5.1% from its 52-week high of $243.32, while the broader market has rallied +25.8% over 90 days and +11.0% over 30 days.

Jazz Pharma EVP Pearce sold 6,907 shares at $235.41; 50.3K shares remain post-transaction

Samantha Pearce, EVP and Chief Commercial Officer, sold 6,907 shares (6.9K shares) of Jazz Pharmaceuticals plc (JAZZ) at $235.41 on 2026-05-28 for total value of $1,625,976.87 ($1.6M), reducing her shareholding from 57,179 shares (57.2K shares) to 50,272 shares (50.3K shares), a -12.1% reduction in that portion of her holdings. The sale occurred at $235.41, which is within the 52-week range of $105.00–$243.32 and represents -4.4% from the 52-week high; the stock has appreciated +14.8% over 30 days and +24.6% over 90 days, indicating recent momentum. The company reported revenue of $1,068,900,000.00 ($1.1B) in the latest quarter with net income of $293,100,000.00 ($293.1M), though it was unprofitable over its most recent full fiscal year, and carries a notably elevated P/E of 494.98 relative to the trailing net income metric. The insider retains 50,272 shares (50.3K shares) of non-derivative holdings and maintains no non-qualified stock options, indicating a partial reduction rather than a full position exit.